New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
07:09 EDTLGND, SPPILigand Pharmaceuticals deal positive, says Cantor
After Ligand Pharmaceuticals (LGND) announced a license and global supply agreement with Spectrum Pharmaceuticals (SSPI) on Captisol-enabled Melphalan for the treatment of multiple myeloma, Cantor believes the deal is "attractive" for Ligand. The firm, which maintains a Hold rating on Ligand, indicates that it is close to upgrading the stock, but is not doing so because it is still concerned about the company's Promacta generic filer announcement.
News For LGND;SPPI From The Last 14 Days
Check below for free stories on LGND;SPPI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
09:33 EDTLGNDGlaxoSmithKline reports record Promacta/Revolade Q2 revenue of $92M
Subscribe for More Information
July 22, 2014
13:17 EDTLGNDLigand reports partner SAGE receives fast track designation for SAGE-547
Subscribe for More Information
July 17, 2014
08:02 EDTLGNDLigand sees Q2 revenue $10.6M, above previous guidance of $9M-$9.5M
Subscribe for More Information
08:01 EDTLGNDLigand board authorizes $10M repurchase program
Subscribe for More Information
July 16, 2014
09:41 EDTLGNDLigand management to meet with Roth Capital
Subscribe for More Information
July 14, 2014
07:20 EDTLGNDControlled Released Society to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use